Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. News
Jul 15, 2025 - globenewswire.com
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
Jul 7, 2025 - globenewswire.com
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Jun 25, 2025 - seekingalpha.com
Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval
Jun 25, 2025 - globenewswire.com
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
Aquestive Therapeutics, Inc. Quantitative Score
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Aquestive Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Aquestive Therapeutics, Inc. Financials
Table Compare
Compare AQST metrics with: | |||
|---|---|---|---|
Earnings & Growth | AQST | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AQST | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AQST | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AQST | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Aquestive Therapeutics, Inc. Income
Aquestive Therapeutics, Inc. Balance Sheet
Aquestive Therapeutics, Inc. Cash Flow
Aquestive Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Aquestive Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Mr. Alexander Mark Schobel | Chief Innovation & Technology Officer |
| Mr. Daniel Barber | Chief Executive Officer, President & Director |
| Ms. Lori J. Braender BSBA, Esq., J.D. | Chief Legal Officer, Chief Compliance Officer & Secretary |
| Mr. A. Ernest Toth Jr. | Chief Financial Officer |
| Ms. Sherry Korczynski | Senior Vice President of Sales & Marketing |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Alexander Mark Schobel | Chief Innovation & Technology Officer | Male | 1959 | 2.6M |
| Mr. Daniel Barber | Chief Executive Officer, President & Director | Male | 1976 | 1.1M |
| Ms. Lori J. Braender BSBA, Esq., J.D. | Chief Legal Officer, Chief Compliance Officer & Secretary | Female | 1956 | 737.77K |
| Mr. A. Ernest Toth Jr. | Chief Financial Officer | Male | 1959 | 667.19K |
| Ms. Sherry Korczynski | Senior Vice President of Sales & Marketing | Female | 1970 | -- |
Aquestive Therapeutics, Inc. Insider Trades
| Date | 11 Jun |
| Name | BROWN GREGORY B |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 42000 |
| Date | 11 Jun |
| Name | Krop Julie |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 42000 |
| Date | 11 Jun |
| Name | MORRIS TIMOTHY E |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 42000 |
| Date | 11 Jun |
| Name | Jenkins Abigail L. |
| Role | Director |
| Transaction | Disposed |
| Type | A-Award |
| Shares | 42000 |
| Date | 11 Jun |
| Name | Cochran John |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 42000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 11 Jun | BROWN GREGORY B | Director | Acquired | A-Award | 42000 |
| 11 Jun | Krop Julie | Director | Acquired | A-Award | 42000 |
| 11 Jun | MORRIS TIMOTHY E | Director | Acquired | A-Award | 42000 |
| 11 Jun | Jenkins Abigail L. | Director | Disposed | A-Award | 42000 |
| 11 Jun | Cochran John | Director | Acquired | A-Award | 42000 |